The prevalence and influencing factors of post-tuberculosis lung disease: A Meta-analysis

doi:10.19982/j.issn.1000-6621.20240454

Abstract

Abstract:

Objective: To identify the prevalence and influencing factors of post-tuberculosis lung disease. Methods: Computerized search was performed for studies on prevalence and influencing factors of post-tuberculosis lung disease in CNKI, WANFANG DATA, VIP, CBM, Cochrane Library, Medline, Embase, Web of Science and CINAHL database from the time of database establishment to September 2024. Both Chinese and English search words were ‘Tuberculosis, Pulmonary/Pulmonary Consumption/Pulmonary Phthis*/post-tb/post tuberculosis’ ‘Lung Diseases/Disease, Pulmonary’ ‘Factor, Risk/Population at Risk/Risk Scores/Health Correlates/Factor, Social Risk/Risk Factor Scores’ ‘Case-Control Studies/Cohort Studies/Cross-Sectional Studies’. Literature screening, quality assessment, and data extraction were performed independently by 2 investigators, and Meta-analysis was performed using Stata 17.0 software. Results: Twenty papers with a total of 795890 patients were included. Meta-analysis showed that the prevalence of post-tuberculosis lung disease was 33.2% (95%CI: 12.0%-58.8%). Low education level (OR=2.32, 95%CI: 1.51-3.56, P<0.001), low BMI (SMD=-0.39, 95%CI: -0.43--0.34, P<0.001), low income (OR=1.19, 95%CI: 1.08-1.32, P=0.001), urban residence (OR=1.13, 95%CI: 1.09-1.16, P<0.001), combined diabetes (OR=2.37, 95%CI: 2.19-2.55, P<0.001), combined cancer (OR=2.01, 95%CI: 1.85-2.18, P<0.001), times of hospitalization (SMD=0.44, 95%CI: 0.25-0.63, P<0.001) and other factors were influential factors for post-tuberculosis lung disease. Conclusion: There are many factors influencing post-tuberculosis lung disease, nursing staff should address the influencing factors and develop individualized interventions to reduce the occurrence of post-tuberculosis lung disease.

Key words: Tuberculosis, pulmonary, Lung diseases, Prevalence, Meta-analysis

CLC Number:

R521

Song Feier, Mao Yanjun, Xia Qiuyue, Zhou Yang, Lin Huan. The prevalence and influencing factors of post-tuberculosis lung disease: A Meta-analysis[J]. Chinese Journal of Antituberculosis, 2025, 47(3): 322-330. doi: 10.19982/j.issn.1000-6621.20240454

Figures/Tables 6

References 42

[1]	胡鑫洋, 高静韬. 世界卫生组织《2024年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(6): 500-504. doi:10.19983/j.issn.2096-8493.2024164.
[2]	van Kampen SC, Wanner A, Edwards M, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Global Health, 2018, 3(4). doi:10.1136/bmjgh-2018-000745.
[3]	Allwood BW, van der Zalm MM, Amaral AFS, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. Int J Tuberc Lung Dis, 2020, 24(8): 820-828. doi:10.5588/ijtld.20.0067. pmid: 32912387
[4]	Ozoh OB, Ojo OO, Dania MG, et al. Impact of post-tuberculosis lung disease on health-related quality of life in patients from two tertiary hospitals in Lagos, Nigeria. Afr J Thorac Crit Care Med, 2021, 27(2):46-52. doi:10.7196/AJTCCM.2021.v27i2.135.
[5]	Allwood BW, Byrne A, Meghji J, et al. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge. Respiration, 2021, 100(8): 751-763. doi:10.1159/000512531.
[6]	Bansal N, Arunachala S, Kaleem Ullah M, et al. Unveiling Silent Consequences: Impact of Pulmonary Tuberculosis on Lung Health and Functional Wellbeing after Treatment. J Clin Med, 2024, 13(14):4115. doi:10.3390/jcm13144115.
[7]	Everatt R, Kuzmickiene I, Davidaviciene E, et al. Incidence of lung cancer among patients with tuberculosis: a nationwide cohort study in Lithuania. Int J Tuberc Lung Dis, 2016, 20(6): 757-763. doi:10.5588/ijtld.15.0783. pmid: 27155178
[8]	Kamenar K, Hossen S, Gupte AN, et al. Previous tuberculosis disease as a risk factor for chronic obstructive pulmonary disease: a cross-sectional analysis of multicountry, population-based studies. Thorax, 2022, 77(11): 1088-1097. doi:10.1136/thoraxjnl-2020-216500.
[9]	Ivanova O, Hoffmann VS, Lange C, et al. Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14621 people. European Respiratory Review, 2023, 32(168):220221. doi:10.1183/16000617.0221-2022.
[10]	Lew YL, Tan AF, Yerkovich ST, et al. Pulmonary function outcomes after tuberculosis treatment in children: a systematic review and meta-analysis. Arch Dis Child, 2024, 109(3): 188-194. doi:10.1136/archdischild-2023-326151.
[11]	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605. doi:10.1007/s10654-010-9491-z. pmid: 20652370
[12]	曾宪涛, 刘慧, 陈曦, 等. Meta分析系列之四:观察性研究的质量评价工具. 中国循证心血管医学杂志, 2012, 4(4): 297-299.
[13]	Kim T, Choi H, Kim SH, et al. Increased Risk of Incident Chronic Obstructive Pulmonary Disease and Related Hospitalizations in Tuberculosis Survivors: A Population-Based Matched Cohort Study. J Korean Med Sci, 2024, 39(11): e105. doi:10.3346/jkms.2024.39.e105. pmid: 38529575
[14]	Wang Y, Li Z, Li F. Impact of Previous Pulmonary Tuberculosis on Chronic Obstructive Pulmonary Disease: Baseline Results from a Prospective Cohort Study. Comb Chem High Throughput Screen, 2023, 26(1): 93-102. doi:10.2174/1386207325666220406111435.
[15]	Shanmugasundaram K, Talwar A, Madan K, et al. Pulmonary Functions and Inflammatory Biomarkers in Post-Pulmonary Tuberculosis Sequelae. Tuberc Respir Dis (Seoul), 2022, 85(2): 175-184. doi:10.4046/trd.2021.0127.
[16]	Setianingrum F, Rozaliyani A, Adawiyah R, et al. A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL). Thorax, 2022, 77(8): 821-828. doi:10.1136/thoraxjnl-2020-216464.
[17]	Park HY, Kang D, Shin SH, et al. Pulmonary Tuberculosis and the Incidence of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2022, 19(4): 640-648. doi:10.1513/AnnalsATS.202010-1240OC.
[18]	Swain S, Pothal S, Behera A, et al. Treatment outcome among Post TB obstructive airways diseases and COPD: A prospective cohort study. J Family Med Prim Care, 2021, 10(9): 3411-3416. doi:10.4103/jfmpc.jfmpc_2391_20. pmid: 34760766
[19]	Khosa C, Bhatt N, Massango I, et al. Development of chronic lung impairment in Mozambican TB patients and associated risks. BMC Pulm Med, 2020, 20(1): 127. doi:10.1186/s12890-020-1167-1. pmid: 32381002
[20]	Mkoko P, Naidoo S, Mbanga LC, et al. Chronic lung disease and a history of tuberculosis (post-tuberculosis lung disease): Clinical features and in-hospital outcomes in a resource-limited setting with a high HIV burden. S Afr Med J, 2019, 109(3): 169-173. doi:10.7196/SAMJ.2019.v109i3.13366.
[21]	Yakar HI, Gunen H, Pehlivan E, et al. The role of tuberculosis in COPD. Int J Chron Obstruct Pulmon Dis, 2017, 12: 323-329. doi:10.2147/COPD.S116086.
[22]	Gandhi K, Gupta S, Singla R. Risk factors associated with development of pulmonary impairment after tuberculosis. Indian J Tuberc, 2016, 63(1): 34-38. doi:10.1016/j.ijtb.2016.01.006. pmid: 27235942
[23]	Nihues SdSE, Mancuzo EV, Sulmonetti N, et al. Chronic symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients. The Brazilian Journal of Infectious Diseases, 2015, 19(5): 492-497. doi:10.1016/j.bjid.2015.06.005.
[24]	Yu YH, Liao CC, Hsu WH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol, 2011, 6(1): 32-37. doi:10.1097/JTO.0b013e3181fb4fcc.
[25]	Ravimohan S, Kornfeld H, Weissman D, et al. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev, 2018, 27(147):170077. doi:10.1183/16000617.0077-2017.
[26]	Maleche-Obimbo E, Odhiambo MA, Njeri L, et al. Magnitude and factors associated with post-tuberculosis lung disease in low- and middle-income countries: A systematic review and meta-analysis. PLOS Glob Public Health, 2022, 2(12): e0000805. doi:10.1371/journal.pgph.0000805.
[27]	Fiogbe AA, Agodokpessi G, Tessier JF, et al. Prevalence of lung function impairment in cured pulmonary tuberculosis patients in Cotonou, Benin. Int J Tuberc Lung Dis, 2019, 23(2): 195-202. doi:10.5588/ijtld.18.0234. pmid: 30808452
[28]	Silveyra P, Fuentes N, Rodriguez Bauza DE. Sex and Gender Differences in Lung Disease. Adv Exp Med Biol, 2021, 1304: 227-258. doi:10.1007/978-3-030-68748-9_14. pmid: 34019273
[29]	Kligerman S, White C. Epidemiology of lung cancer in women: risk factors, survival, and screening. AJR Am J Roentgenol, 2011, 196(2): 287-295. doi:10.2214/AJR.10.5412.
[30]	Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J, 2014, 43(6): 1763-1775. doi:10.1183/09031936.00193413. pmid: 24525439
[31]	Visca D, Zampogna E, Sotgiu G, et al. Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. Eur Respir J, 2019, 53(3):1802184. doi:10.1183/13993003.02184-2018.
[32]	Kim SJ, Lee J, Park YS, et al. Effect of Airflow Limitation on Acute Exacerbations in Patients with Destroyed Lungs by Tuberculosis. Journal of Korean Medical Science, 2015, 30(6):737-742. doi:10.3346/jkms.2015.30.6.737. pmid: 26028926
[33]	曾谊, 兰学立, 路希维. 重视结核病相关疾病的整合医学管理. 中国防痨杂志, 2024, 46(7): 735-738. doi:10.19982/j.issn.1000-6621.20240173.
[34]	杨澄清, 陈淑芳, 梅春林, 等. 220例肺结核合并慢性肺曲霉病患者的临床特征. 中国防痨杂志, 2024, 46(7): 770-777. doi:10.19982/j.issn.1000-6621.20240129.
[35]	杨蕊, 李玲, 陈金瓯, 等. 2017—2021年云南省肺结核与糖尿病共病患者抗结核治疗效果及影响因素分析. 中国防痨杂志, 2024, 46(5): 519-524. doi:10.19982/j.issn.1000-6621.20240006.
[36]	World Health Organization. Tuberculosis and diabetes: invest for impact: information note. Geneva: World Health Organization, 2023.
[37]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021, 43(1): 12-22. doi:10.3969/j.issn.1000-6621.2021.01.004.
[38]	邓国防. 《结核病与糖尿病共病的治疗管理专家共识》解读. 中国防痨杂志, 2021, 43(4): 318-321. doi:10.3969/j.issn.1000-6621.2021.04.004.
[39]	Moon SM, Choi H, Kim SH, et al. Increased Lung Cancer Risk and Associated Risk Factors in Tuberculosis Survivors: A Korean Population-Based Study. Clin Infect Dis, 2023, 77(9): 1329-1339. doi:10.1093/cid/ciad373. pmid: 37345907
[40]	Hussain A, Khurana AK, Goyal A, et al. Effect of pulmonary rehabilitation in patients with post-tuberculosis sequelae with functional limitation. Indian J Tuberc, 2024, 71(2): 123-129. doi:10.1016/j.ijtb.2023.04.012. pmid: 38589115
[41]	Pontali E, Silva DR, Marx FM, et al. Breathing Back Better! A State of the Art on the Benefits of Functional Evaluation and Rehabilitation of Post-Tuberculosis and Post-COVID Lungs. Archivos de Bronconeumología, 2022, 58(11): 754-763. doi:10.1016/j.arbres.2022.05.010.
[42]	Silva DR, Santos AP, Visca D, et al. Brazilian Thoracic Association recommendations for the management of post-tuberculosis lung disease. J Bras Pneumol, 2024, 49(6): e20230269. doi:10.36416/1806-3756/e20230269.

序号	检索词
#1	(((((″tuberculosis, pulmonary″[Mesh]) OR (pulmonary consumptions[Title/Abstract])) OR (pulmonary phthis*[Title/Abstract])) OR (pulmonary tuberculoses[Title/Abstract])) OR (post-tb[Title/Abstract])) OR (post tuberculoses[Title/Abstract])
#2	(″lung diseases″[Mesh]) OR (disease, pulmonary[Title/Abstract])
#3	(((((″risk factors″[Mesh]) OR (population at risk[Title/Abstract])) OR (risk scores[Title/Abstract])) OR (risk factor scores[Title/Abstract])) OR (health correlates[Title/Abstract])) OR (factor, social risk[Title/Abstract])
#4	(((((″case-control studies″[Mesh]) OR (case-comp* studies[Title/Abstract])) OR (case-base studies[Title/Abstract])) OR (case-referent studies[Title/Abstract])) OR (matched case-control studies[Title/Abstract])) OR (nested case-control studies[Title/Abstract])
#5	((((((″cohort studies″[Mesh]) OR (studies, concurrent[Title/Abstract])) OR (cohort studies, closed[Title/Abstract])) OR (cohort studies, historical[Title/Abstract])) OR (incidence studies[Title/Abstract])) OR (analys*, cohort[Title/Abstract])) OR (birth cohort studies[Title/Abstract])
#6	((((″cross-sectional studies″[Mesh]) OR (cross-sectional survey[Title/Abstract])) OR (surveys, disease frequency[Title/Abstract])) OR (analys*, cross-sectional[Title/Abstract])) OR (prevalence studies[Title/Abstract])
#7	#4 OR #5 OR #6
#8	#1 AND #2 AND #3 AND #7

纳入文献	发表时间	研究地区	研究类型	研究对象	影响因素	患病率 (%)	质量评分 (分)
Kim等^[13]	2024年	韩国	队列研究	肺结核相关阻塞性肺疾病	③⑤⑧⑩ ??????	50.0	7
Wang等^[14]	2023年	中国	队列研究	肺结核相关阻塞性肺疾病	①④???	2.7	6
Shanmugasundaram等^[15]	2022年	印度	病例对照研究	肺结核病后遗症	⑤	50.0	7
Setianingrum等^[16]	2022年	印度尼西亚	队列研究	肺结核后慢性肺曲霉菌病	②	5.6	7
Park等^[17]	2022年	韩国	队列研究	肺结核相关阻塞性肺疾病	①③⑤⑧?	17.8	7
Swain等^[18]	2021年	印度	队列研究	肺结核相关阻塞性肺疾病	①②③⑤⑥⑦⑨	50.7	7
Khosa等^[19]	2020年	南非	队列研究	肺结核后肺功能损伤	②③	64.5	8
Mkoko等^[20]	2019年	南非	病例对照研究	肺结核后慢性肺部疾病	??	71.5	6
Yakar等^[21]	2017年	土耳其	队列研究	肺结核相关阻塞性肺疾病	①⑦⑨	15.0	7
Gandhi等^[22]	2016年	印度	病例对照研究	肺结核后肺功能损伤	③④⑤?	74.0	7
Nihues等^[23]	2015年	巴西	横断面	肺结核病后慢性肺部疾病	②④??	45.0	8
Yu等^[24]	2011年	中国台湾	队列研究	肺结核后肺癌	①②⑩????	0.6	7

亚组	纳入研究文献数量	异质性检验结果		效应模型	Meta分析结果
亚组	纳入研究文献数量	I²值(%)	P值	效应模型	OR(95%CI)值	P值
疾病类型
结核相关阻塞性肺疾病	5	99.958	<0.001	随机	0.243(0.066~0.484)	<0.001
其他类型疾病	7	99.671	<0.001	随机	0.401(0.078~0.783)	0.002
研究年份
2011—2019年	7	99.936	<0.001	随机	0.303(0.124~0.519)	<0.001
2020—2024年	5	99.782	<0.001	随机	0.368(0.061~0.756)	0.002

影响因素	纳入研究数	异质性检验结果		效应模型	Meta分析结果
影响因素	纳入研究数	I²值(%)	P值	效应模型	合并效应量	95%CI值	P值
一般资料
年龄	4	94.1	<0.001	随机	SMD=-0.12	(-0.50~0.25)	0.526
性别(女)	4	48.9	0.118	固定	OR=2.46	(1.20~5.04)	0.014
吸烟(是)	5	96.5	<0.001	随机	OR=0.84	(0.56~1.27)	0.413
受教育程度(低)	3	0.0	0.424	固定	OR=2.32	(1.51~3.56)	<0.001
BMI	5	0.0	0.876	固定	SMD=-0.39	(-0.43~-0.34)	<0.001
收入(低)	4	53.1	0.094	随机	OR=1.19	(1.08~1.32)	0.001
居住地(城市)	2	0.0	0.366	固定	OR=1.13	(1.09~1.16)	<0.001
并发症(是)
糖尿病	2	98.1	<0.001	随机	OR=2.01	(1.85~2.18)	<0.001
高血压	2	99.9	<0.001	随机	OR=1.60	(0.52~4.86)	0.410
血脂异常	2	99.3	<0.001	随机	OR=1.54	(0.90~2.62)	0.114
癌症	2	0.0	0.360	固定	OR=2.01	(1.85~2.18)	<0.001
不良事件
急性加重的严重程度	2	89.8	0.002	随机	OR=3.71	(0.85~16.28)	0.082
住院频率	2	0.0	0.919	固定	SMD=0.44	(0.25~0.63)	<0.001